| STAT3 Inhibitor for Solid Tumors (NCT00955812) | M.D. Anderson Cancer Center | 2009-06-01 |
| Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors (NCT00920595) | Cephalon | 2009-06-01 |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib (NCT00920868) | Herbert Hurwitz, MD | 2009-05-01 |
| Clinical Study of Liposomal Paclitaxel in Chinese Patients (NCT00881101) | Nanjing Sike Pharmaceutical Co., Ltd. | 2009-04-01 |
| A Study of of MORAb-004 in Subjects With Solid Tumors (NCT00847054) | Morphotek | 2009-03-01 |
| A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies (NCT00840190) | Piramal Enterprises Limited | 2008-12-01 |
| Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan (NCT00742105) | Novartis Pharmaceuticals | 2008-11-17 |
| A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors (NCT00786669) | Children's Hospital Medical Center, Cincinnati | 2008-10-01 |
| Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) (NCT00781846) | Merck Sharp & Dohme LLC | 2008-10-01 |
| A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram (NCT00786838) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-10-01 |
| A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread (NCT01648764) | Eli Lilly and Company | 2008-09-01 |
| A Phase 1 Study of ABT-869 in Subjects With Solid Tumors (NCT00718380) | AbbVie | 2008-09-01 |
| Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. (NCT00753740) | NewLink Genetics Corporation | 2008-09-01 |
| Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device (NCT00867295) | Istanbul University | 2008-09-01 |
| Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients (NCT01134250) | Philogen S.p.A. | 2008-08-06 |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies (NCT00736749) | Children's Oncology Group | 2008-07-17 |
| Solid Tumors Using Ixabepilone and Dasatinib (NCT00717704) | Medstar Health Research Institute | 2008-07-01 |
| Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) (NCT02575638) | Cao Pharmaceuticals Inc. | 2008-07-01 |
| Opioids Titration in Hospice Patients (NCT01007422) | Vanderbilt-Ingram Cancer Center | 2008-06-01 |
| AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours (NCT00704366) | AstraZeneca | 2008-06-01 |
| A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors (NCT00721669) | ImmunoGen, Inc. | 2008-06-01 |
| Safety Study of CALAA-01 to Treat Solid Tumor Cancers (NCT00689065) | Calando Pharmaceuticals | 2008-05-01 |
| An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors (NCT00657176) | Korea Otsuka Pharmaceutical Co., Ltd. | 2008-03-01 |
| Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours (NCT00697879) | Chroma Therapeutics | 2008-02-01 |
| Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer (NCT00499668) | Vanderbilt-Ingram Cancer Center | 2007-08-01 |
| Pain Control in Hospice Patients With Cancer-Related Pain (NCT00609297) | Vanderbilt-Ingram Cancer Center | 2007-07-01 |
| Study of Cobimetinib in Participants With Solid Tumors (NCT00467779) | Genentech, Inc. | 2007-05-01 |
| Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor (NCT00638898) | City of Hope Medical Center | 2007-02-26 |
| Voraxaze for Delayed Methotrexate Clearance (NCT00424645) | M.D. Anderson Cancer Center | 2007-01-01 |
| RTA 744 Injection in Patients With Leptomeningeal Disease (NCT00512460) | M.D. Anderson Cancer Center | 2006-09-01 |
| A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours (NCT00737555) | Chroma Therapeutics | 2006-08-01 |
| Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma (NCT00413075) | Valerio Therapeutics | 2006-06-01 |
| Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors (NCT00333502) | NewLink Genetics Corporation | 2006-05-01 |
| Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer (NCT00898027) | Vanderbilt-Ingram Cancer Center | 2006-05-01 |
| Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes (NCT00300001) | Community Cancer Care | 2006-03-01 |
| Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors (NCT00624962) | Vanderbilt University | 2006-03-01 |
| Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases (NCT00469937) | Vanderbilt-Ingram Cancer Center | 2006-02-01 |
| Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients (NCT00483457) | Vanderbilt-Ingram Cancer Center | 2006-02-01 |
| Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) (NCT00701103) | Merck Sharp & Dohme LLC | 2006-01-12 |
| Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy (NCT00803556) | Bristol-Myers Squibb | 2006-01-01 |
| A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors (NCT02884128) | PharmaEngine | 2006-01-01 |
| Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202 (NCT00896662) | Vanderbilt-Ingram Cancer Center | 2005-01-01 |
| Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma (NCT00470405) | Vanderbilt-Ingram Cancer Center | 2004-05-01 |
| A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors (NCT02490475) | Hoffmann-La Roche | 2004-02-01 |
| A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors (NCT02494596) | Hoffmann-La Roche | 2004-01-01 |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma (NCT00512798) | Vanderbilt-Ingram Cancer Center | 2003-06-01 |
| Phase II Study for Solid Metastatic Tumors (NCT02474186) | NYU Langone Health | 2003-04-01 |
| LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors (NCT00052273) | Jonsson Comprehensive Cancer Center | 2002-12-01 |
| A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation (NCT00894049) | Institut Paoli-Calmettes | 2002-11-01 |
| Simultaneous Care: Linking Palliation to Clinical Trials (NCT00283257) | University of California, Davis | 2002-02-01 |
| Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies (NCT00215501) | Dana-Farber Cancer Institute | 2001-11-01 |
| Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies (NCT00251407) | Dana-Farber Cancer Institute | 1999-09-01 |
| MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer (NCT06980519) | Monopar Therapeutics | |
| MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer (NCT06980506) | Monopar Therapeutics | |
| Expanded Access of Vigil in Solid Tumors (NCT03842865) | Gradalis, Inc. | |